Brief: Jazz Pharmaceuticals Q2 Adjusted EPS USD -8.25 Vs. IBES Estimate USD -7.61

Jazz Pharmaceuticals

05/08/2025 21:05

Overview

Jazz Pharmaceuticals Q2 rev rises 2%

Adjusted EPS for Q2 misses consensus, impacted by Chimerix acquisition expenses

Co repurchased shares worth $125 mln, part of $500 mln authorization

Outlook

Jazz Pharmaceuticals updates 2025 revenue guidance to $4.15-$4.30 bln

Company expects multiple oncology catalysts to drive revenue growth

Jazz Pharmaceuticals anticipates blockbuster status for Epidiolex in 2025

Company projects improved effective tax rate for 2025

Result Drivers

XYWAV GROWTH - Xywav revenues grew 13% year-over-year, driven by net patient additions of 625

ZEPZELCA DECLINE - Zepzelca sales fell 8% due to increased competition and treatment protocol updates

CHIMERIX IMPACT - Acquisition of Chimerix contributed to adjusted EPS miss due to associated expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$1.05 bln
$1.05 bln (16 Analysts)
Q2 Adjusted EPS
Miss
-$8.25
-$7.61 (14 Analysts)
Q2 EPS
-$11.74
Q2 Adjusted Net Income
Miss
-$504.85 mln
-$459.90 mln (12 Analysts)
Q2 Net Income
-$718.47 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Jazz Pharmaceuticals PLC is $178.21, about 34.9% above its August 4 closing price of $116.10

The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release: ID:nPn59fbNBa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)